KNSA Kiniksa Pharmaceuticals, Ltd.

NASDAQ
$78.75

Kiniksa Pharmaceuticals, Ltd. (KNSA) Institutional Ownership

What the institutions did with KNSA last quarter, from their 13F filings. Counting managers rather than shares is the point: a single index fund adding to a position tells you far less than four hundred separate managers all deciding to. Positions as reported for the quarter ended September 30, 2026.

Managers compared
2
filed both this quarter and last
Managers holding
2
+1 on the quarter
Buyers
2
1 opened new
Sellers
0
0 sold out entirely
Buyer share
100.0%
of managers who traded it
Breadth
+100.0
net buyers, as a share of those trading

Only 2 managers reported a position this quarter, so the percentages above describe a very small sample.

Every manager below opens. Subscribers can see any firm's whole portfolio — every position, its weight, and what they bought, trimmed and exited last quarter.

Sign in or subscribe

Largest holders

Manager Shares % of reported
Versant Capital Management, Inc 186 98.4%
MassMutual Private Wealth & Trust, FSB 3 1.6%

Largest changes

Manager Action Previous Current Change
Versant Capital Management, Inc Increased 166 186 +20
MassMutual Private Wealth & Trust, FSB New 0 3 +3

13F filings are due 45 days after quarter end and cover long positions in U.S.-listed equities only, so this is a lagged and partial picture: shorts, bonds and foreign listings never appear. Options positions are excluded here rather than folded into the share counts. Political ownership is coming.